MicrosensDx is excited to announce that it is working with The Mayr Group at Imperial College London to develop a novel biomarker test for the early recognition of sepsis. Based on MicrosensDx’s IP and technology, and designed to fit with existing diagnostic processes, this test could potentially fill a critical gap in patient management, offering clinicians a specific, quantitative diagnostic and prognostic solution to help prioritise appropriate treatment of sepsis. Sepsis is a very serious disease affecting 49 million people globally.
It results in 13 million deaths annually – and is implicated in 20 percent of all deaths – imposing a staggering £15.6 billion cost per year on the UK alone. There is a clear need for routine testing to enable more specific detection and prioritisation of sepsis treatment, as current biomarkers focus mainly on detecting inflammation, and most proposed biomarkers have limitations.
A successful test to profile the risk of sepsis could therefore improve treatment, enable more timely and appropriate interventions, and reduce costs. MicrosensDx and Imperial are applying their joint expertise and experience in infectious diseases to address this challenge, with the aim of developing a groundbreaking sepsis test based on the detection of P Complex, which increases during serious infection, with high levels linked to poor patient outcomes. The team is working on an early stage project to evaluate the efficacy of specific antibodies against P C.